Email this article 
Therapeutic Dimensions of Bisphosphonates: A Clinical Update
Abstract
Keywords
Full Text:
PDFReferences
Aggarwal S, Gahlot N, Saini UC, Dillon MS. Bisphosphonates
in orthopedics: Evidence‑based review of indications and adverse
effects. J Postgrad Med Educ Res 2016;50:75‑85.
Widler L, Jaeggi KA, Glatt M, Müller K, Bachmann R,
Bisping M, et al. Highly potent geminal bisphosphonates. From
pamidronate disodium (Aredia) to zoledronic acid (Zometa).
J Med Chem 2002;45:3721‑38.
Grey A, Reid IR. Differences between the bisphosphonates for
the prevention and treatment of osteoporosis. Ther Clin Risk
Manag 2006;2:77.
Dunford JE, Kwaasi AA, Rogers MJ, Barnett BL, Ebetino FH,
Russell RG, et al. Structure–activity relationships among the
nitrogen containing bisphosphonates in clinical use and other
analogues: Time‑dependent inhibition of human farnesyl
pyrophosphate synthase. J Med Chem 2008;51:2187‑95.
Ziel HK, Finkle WD. Increased risk of endometrial carcinoma
among users of conjugated estrogens. N Engl J Med
;293:1167‑70.
Krishnan S, Pandian S, Kumar A. Effect of bisphosphonates
on orthodontic tooth movement‑an update. J Clin Diagn Res
;9:ZE01‑5.
Fleurence RL, Iglesias CP, Johnson JM. The cost effectiveness of
bisphosphonates for the prevention and treatment of osteoporosis.
Pharmacoeconomics 2007;25:913‑33.
Ezra A, Golomb G. Administration routes and delivery systems
of bisphosphonates for the treatment of bone resorption. Adv
Drug Deliv Rev 2000;42:175‑95.
Widler L, Jahnke W, R Green J. The chemistry of
bisphosphonates: From antiscaling agents to clinical therapeutics.
Anticancer Agents Med Chem 2012;12:95‑101.
Graham R, Russell G. The bisphosphonate odyssey. A journey
from chemistry to the clinic. Phosphorus Sulfur Silicon Relat
Elem 1999;144:793‑820.
Chemistry and classes of Bisphosphonates. Indian orthopedia
research group. Available from: http://www.iorg.co.in/2442‑2/.
[Last assessed on 2019 Aug 28].
Bisphosphonates. In: IBM Micromedex® DRUGDEX®
(electronic version). Truven Health Analytics, Greenwood
Village, Colorado, USA. Available from: http://www.
micromedexsolutions.com/. [Last cited on 2018 Jul 02].
McEvoy GK, editor. AHFS Drug Information. Bethesda:
American Society of Health System Pharmacist; 2004.
Watts NB, Bilezikian JP, Camacho PM, Greenspan SL,
Harris ST, Hodgson SF, et al. American Association of Clinical
Endocrinologists Medical Guidelines for Clinical Practice for the
diagnosis and treatment of postmenopausal osteoporosis Endocr
Pract 2010;16(Suppl 3):1‑37.
Compston J, Bowring C, Cooper A, Cooper C, Davies C,
Francis R, et al. Diagnosis and management of osteoporosis
in postmenopausal women and older men in the UK: National
Osteoporosis Guideline Group (NOGG) update 2013. Maturitas
;75:392‑6.
Management of osteoporosis in postmenopausal women: 2010
position statement of The North American Menopause Society.
Menopause 2010;17:25‑54; quiz 55‑6.
Drake MT, Clarke BL, Khosla S. Bisphosphonates: Mechanism
of action and role in clinical practice. Mayo Clin Proc
;83:1032‑45.
Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ.
Alendronate increases bone strength by increasing the mean
degree of mineralization of bone tissue in osteoporotic women.
Bone 2000;27:687‑94.
Eriksen EF, Díez‑Pérez A, Boonen S. Update on long‑term
treatment with bisphosphonates for postmenopausal osteoporosis:
A systematic review. Bone 2014;58:126‑35.
Black DM, Cummings SR, Karpf DB, Cauley JA,
Thompson DE, Nevitt MC, et al. Fracture Intervention Trial
Research Group. Randomised trial of effect of alendronate
on risk of fracture in women with existing vertebral fractures.
Lancet 1996;348:1535‑41.
Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T,
Keller M, et al. Vertebral efficacy with risedronate therapy
(VERT) study group. Effects of risedronate treatment
on vertebral and nonvertebral fractures in women with
postmenopausal osteoporosis: A randomized controlled trial.
JAMA 1999;82:1344‑52.
Gauthier K, Bai A, Perras C, Cunningham J, Ahuja T,
Richter T, et al. Denosumab, Raloxifene, and Zoledronic Acid
for the Treatment of Postmenopausal Osteoporosis: Clinical
Effectiveness and Harms. Rapid Response Report: Systematic
Review. Ottawa: Canadian Agency for Drugs and Technologies
in Health. Available from: https://www.ncbi.nlm.nih.gov/books/
NBK169524/. [Last assessed on 2019 Aug 28].
Lomer MC. Dietary and nutritional considerations for
inflammatory bowel disease. Proc Nutr Soc 2011;70:329‑35.
Gerasimidis K, McGrogan P, Edwards CA. The aetiology and
impact of malnutrition in paediatric inflammatory bowel disease.
J Hum Nutr Diet 2011;24:313‑26.
Trikudanathan G, Venkatesh PG, Navaneethan U. Diagnosis and
therapeutic management of extra‑intestinal manifestations of
inflammatory bowel disease. Drugs 2012;72:2333‑49.
Bernstein M, Irwin S, Greenberg GR. Maintenance infliximab
treatment is associated with improved bone mineral density in
Crohn’s Disease”. Am J Gastroenterol 2005;100:2031‑5.
Product Information: FOSAMAX (R) oral tablets, oral solution,
alendronate sodium oral tablets, oral solution. Merck Sharp &
Dohme Corp. (per FDA), Whitehouse Station, NJ, 2012.
Ringe JD, Dorst A, Faber H, Ibach K, Sorenson F. Intermittent
intravenous ibandronate injections reduce vertebral fracture risk
in corticosteroid induced osteoporosis: Results from a long‑term
comparative study. Osteoporos Int 2003;14:801‑7.
Krieg MA, Seydoux C, Sandini L, Goy JJ, Berguer DG, Thie D,
et al. Intravenous pamidronate as treatment for osteoporosis
after heart transplantation: A prospective study. Osteoporosis Int
;12:112‑6.
Rao SS, Budhwar N, Ashfaque A. Osteoporosis in men. Am Fam
Physician 2010;82:503‑8.
Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B,
Oglesby AK. The components of excess mortality after hip
fracture. Bone 2003;32:468‑73.
Haentjens P, Magaziner J, Colón‑Emeric CS, Vanderschueren D,
Milisen K, Velkeniers B, et al. Meta‑analysis: Excess mortality
after hip fracture among older women and men. Ann Intern Med
;152:380‑90.
Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA.
Mortality after all major types of osteoporotic fracture in men
and women: An observational study. Lancet 1999;353:878‑82.
Ebeling PR. Clinical practice. Osteoporosis in men. N Engl J
Med 2008;358:1474‑82.
Khosla S, Amin S, Orwoll E. Osteoporosis in men. Endocr Rev
;29:441‑64.
Mazziotti G, Angeli A, Bilezikian JP, Canalis E,
Giustina A. Glucocorticoid‑induced osteoporosis: An update.
Trends Endocrinol Metab 2006;17:144‑9.
Angeli A, Guglielmi G, Dovio A, Capelli G, de Feo D, Giannini S,
et al. High prevalence of asymptomatic vertebral fractures in
postmenopausal women receiving chronic glucocorticoid therapy:
A cross‑sectional outpatient study. Bone 2006;39:253‑9.
Reid IR. Glucocorticoid‑induced osteoporosis: Assessment and
treatment. J Clin Densitom 1998;1:65‑73.
Maricic M, Gluck O. Densitometry in glucocorticoid‑induced
osteoporosis. J Clin Densitom 2004;7:359‑63.
Curtis JR, Westfall AO, Allison J, Becker A, Melton ME,
Freeman A, et al. Challenges in improving the quality
of osteoporosis care for long‑term glucocorticoid users:
A prospective randomized trial. Arch Intern Med 2007;167:591‑6.
de Nijs RN, Jacobs JW, Lems WF, Laan RF, Algra A,
Huisman AM, et al. STOP Investigators. Alendronate or
alfacalcidol in glucocorticoid‑induced osteoporosis. N Engl J
Med 2006;355:675‑84.
Boutsen Y, Jamart J, Esselinckx W, Stoffel M, Devogelaer JP.
Primary prevention of glucocorticoid‑induced osteoporosis with
intermittent intravenous pamidronate: A randomized trial. Calcif
Tissue Int 1997;61:266‑71.
Gilchrist NL, Frampton CM, Acland RH, Nicholls MG,
March RL, Maguire P, et al. Alendronate prevents bone loss
in patients with acute spinal cord injury: A randomized,
double‑blind, placebo‑controlled study. J Clin Endocrinol Metab
;92:1385‑90.
Nance PW, Schryvers O, Leslie W, Ludwig S, Krahn J,
Uebelhart D. Intravenous pamidronate attenuates bone density
loss after acute spinal cord. injury. Arch Phys Med Rehabil.
;80:243‑51.
Whyte MP. Paget’s disease of bone. N Engl J Med
;355:593‑600.
Ralston SH. Paget’s disease of bone. N Engl J Med
;368:644‑50.
Singer FR, Bone HG, Hosking DJ, Lyles KW, Murad MH,
Reid IR, et al. Paget’s disease of bone: An endocrine
society clinical practice guideline. J Clin Endocrinol Metab
;99:4408‑22.
Siris E, Weinstein RS, Altman R, Conte JM, Favus M,
Lombardi A, et al. Comparative study of alendronate versus
etidronate for the treatment of Paget’s disease of bone. J Clin
Endocrinol Metab 1996;81:961‑7.
Siris ES, Chines AA, Altman RD, Brown JP, Johnston CC Jr,
Lang R, et al. Risedronate in the treatment of Paget’s disease
of bone: An open label, multicenter study. J Bone Miner Res
;13:1032‑8.
Product Information: SKELID(R) oral tablets, tiludronate
disodium oral tablets. Sanofi‑Aventis U.S. LLC, Bridgewater, NJ,
Siris ES. Perspectives: A practical guide to the use of
pamidronate in the treatment of Paget’s disease. J Bone Miner
Res 1994;9:303‑4.
Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y,
et al. Comparison of a single infusion of zoledronic acid with
risedronate for Paget’s disease. N Engl J Med 2005;353:898‑908.
Green JR. Antitumour effects of bisphosphonates. Cancer
;97 (3 Suppl):840‑7.
Van Acker HH, Anguille S, Willemen Y, Smits EL,
Van Tendeloo VF. Bisphosphonates for cancer treatment:
Mechanisms of action and lessons from clinical trials. Pharmacol
Ther 2016;158:24‑40.
Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V. Oral
bisphosphonates and risk of cancer of oesophagus, stomach, and
colorectum: Case–control analysis within a UK primary care
cohort. BMJ 2010;341:c4444.
Cardwell CR, Abnet CC, Cantwel MM, Murray LJ. Exposure
to oral bisphosphonates and risk of oesophageal cancer. JAMA
;304:657‑63.
Wu S, Dahut WL, Gulley JL. The use of bisphosphonates in
cancer patients. Acta Oncologica 2007;46:581‑91.
Clezardin P. The antitumor potential of bisphosphonates. Semin
Oncol 2002;29 (6 Suppl 21):33‑42.
Lee MV, Fong EM, Singer FR, Guenette RS. Bisphosphonate
inhibits the growth of prostate cancer cells. Cancer Res
;61:2602‑8.
Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A,
et al. Randomized, placebo‑controlled trial of clodronate in patients
with primary operable breast cancer. J Clin Oncol 2002;20:3219‑24.
Gnant MF, Mlineritsch B, Luschin‑Ebengreuth G, Grampp S,
Kaessmann H, Schmid M, et al. Zoledronic acid prevents cancer
treatment‑induced bone loss in premenopausal women receiving
adjuvant endocrine therapy for hormone‑responsive breast
cancer: A report from the Austrian Breast and Colorectal Cancer
Study Group. J Clin Oncol 2007;25:820‑8.
Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J,
Delmas PD. Estrogen‑dependent increase in bone turnover and
bone loss in postmenopausal women with breast cancer treated
with anastrozole: Prevention with bisphosphonates. Bone
;41:346‑52.
Rodan GA. Mechanisms of action of bisphosphonates. Ann Rev
Pharmacol Toxicol 1998;38:375‑88.
Oades GM, Coxon J, Colston KW. The potential role of
bisphosphonates in prostate cancer. Prostate Cancer Prostatic Dis
;5:264‑72.
Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P,
Lacombe L, et al. Zoledronic Acid Prostate Cancer Study Group.
A randomized, placebo‑controlled trial of zoledronic acid in
patients with hormone‑refractory metastatic prostate carcinoma.
J Natl Cancer Inst 2002;94:1458‑68.
Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P,
Lacombe L, et al. Long‑term efficacy of zoledronic acid
for the prevention of skeletal complications in patients with
metastatic hormone‑refractory prostate cancer. J Natl Cancer Inst
;96:879‑82.
Han SH, de Klerk JM, Tan S, van het Schip AD, Derksen BH,
van Dijk A, et al. The placorhen study: A double‑blind,
placebo‑controlled, randomized radionuclide study with
Re‑etidronate in hormone‑resistant prostate cancer patients
with painful bone metastases. J Nucl Med 2002;43:1150‑6.
Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL,
Schoenfeld DA, et al. Pamidronate to prevent bone loss during
androgen‑deprivation therapy for prostate cancer. N Engl J Med
;345:948‑55.
Michaelson MD, Kaufman DS, Lee H, McGovern FJ,
Kantoff PW, Fallon MA, et al. Randomized controlled trial
of annual zoledronic acid to prevent gonadotropin‑releasing
hormone agonist‑induced bone loss in men with prostate cancer.
J Clin Oncol 2007;25:1038‑42.
Ishizaka K, Machida T, Kobayashi S, Kanbe N, Kitahara S,
Yoshida K. Preventive effect of risedronate on bone loss in men
receiving androgendeprivation therapy for prostate cancer. Int J
Urol 2007;14:1071‑5.
Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC.
Multiple myeloma. Lancet 2009;374:324‑39.
Heusschen R, Muller J, Cithofs N, Caron F, Ceguin Y, Caers J.
Multiple myeloma bone disease: From mechanisms to next
generation therapy. Belgian J Hematol 2017;8:66‑74.
Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE,
Morley W, et al. Zoledronic acid reduces skeletal-related
events in patients with osteolytic metastases: A double-blind,
randomized dose–response study. Cancer 2001;91:1191‑200.
Rosen LS, Gordon D, Kaminski M, Howell A, Belch A,
Mackey J, et al. Zoledronic acid versus pamidronate in the
treatment of skeletal metastases in patients with breast cancer or
osteolytic lesions of multiple myeloma: A phase III, double‑blind,
comparative trial. Cancer J 2001;7:377‑87.
Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL,
Hayman SR, et al. Mayo Clinic consensus statement for the
use of bisphosphonates in multiple myeloma. Mayo Clin Proc
;81:1047‑53.
Osteogenesis imperfect. Genetics Home Reference. 11 October 2016.
Plotkin H. Syndromes with congenital brittle bones. BMC
Pediatr 2004;4:16.
Osteogenesis Imperfecta Overview. NIAMS. 2014 Jun. Available
from: https://www.niams.nih.gov/health‑topics/osteogenesisimperfecta. [Last assessed on 2019 Aug 28].
What Is Osteogenesis Imperfecta? Fast Facts: An Easy‑to‑Read
Series of Publications for the Public. NIAMS. 2014 Nov.
Available from: https://niamsdemo.demo6.iqsolutions.
com/health.../Osteogenesis_Imperfecta/. [Last assessed on
Aug 28].
Devogelaer JP, Malghem J, Maldague B,
Nagat de Deuxchaisnes C. Radiological manifestations of
bisphosphonate treatment with APD in a child suffering from
osteogenesis imperfecta. Skeletal Radiol 1987;16:360‑3.
Harrington J, Sochett E, Howard, A. Update on the evaluation
and treatment of osteogenesis imperfecta. Pediatr Clin North Am
;61:1243‑57.
Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate
therapy for osteogenesis imperfecta. Cochrane Database Syst
Rev 2016;10:CD005088.
Byers PH. Osteogenesis imperfecta: Perspectives and
opportunities. Pediatrics 2000;12:603‑09.
US Food and Drug Administration: Update of Safety Review
Follow‑Up to the October 1, 2007 Early Communication about
the Ongoing Safety Review of Bisphosphonates. Rockville, MD:
US Food and Drug Administration; 2008.
United States Food and Drug Administration: Early Communication
of an Ongoing Safety Review: Bisphosphonates. Rockville, MD:
United States Food and Drug Administration; 2007.
Grove EL, Abrahamsen B, Vestergaard P. Heart failure in patients
treated with bisphosphonates. J Intern Med 2013;274:342‑50.
Cummings SR, Schwartz AV, Black DM. Alendronate and atrial
fibrillation. N Engl J Med 2007;356:1895‑6.
Product Information: Aredia(R) Intravenous Injection,
Pamidronate Disodium Intravenous Injection. East Hanover, NJ:
Novartis Pharmaceuticals Corporation (per FDA); 2012.
Harinck HIJ, Papapoulos SE, Blanksma HJ, Moolenaar AJ,
Vermeij P, Bijvoet OL. Paget’s disease of bone: Early and
late responses to three different modes of treatment with
aminohydroxypropylidene biphosphonate (APD). Br Med J
;295:1301‑5.
Ralston SH, Gardner MD, Dryburgh FJ, Jenkins AS,
Cowan RA, Boyle IT. Comparison of aminohydroxypropylidene
diphosphonate, mithramycin, and corticosteroids/calcitonin
in treatment of cancer‑associated hypercalcaemia. Lancet
;2:907‑10.
Product Information: Actonel(R) Oral Tablets, Risedronate
Sodium Oral Tablets. Rockaway, NJ: Warner Chilcott (US),
LLC (per FDA); 2013.
Black DM, Delmas PD, Eastell R, Reid IR, Boonen S,
Cauley JA, et al. Once‑yearly zoledronic acid for treatment of
postmenopausal osteoporosis. N Engl J Med 2007;356:1809‑22.
Lyles KW, Colon‑Emeric CS, Magaziner JS, Adachi JD,
Pieper CF, Mautalen C, et al. HORIZON Recurrent Fracture
Trial. Zoledronic acid and clinical fractures and mortality after
hip fracture. N Engl J Med 2007;357:1799‑809.
Bundred NJ, Campbell ID, Davidson N, DeBoer RH,
Eidtmann H, Monnier A, et al. Effective inhibition of aromatase
inhibitor‑associated bone loss by zoledronic acid in postmenopausal
women with early breast cancer receiving adjuvant letrozole:
ZO‑FAST Study results. Cancer 2008;112:1001‑10.
Product Information: FOSAMAX(R) Oral Tablets, Solution,
Alendronate Sodium Oral Tablets, Solution. Whitehouse Station,
NJ: Merck Sharp & Dohme Corp (per manufacturer); 2011.
Reynolds JEF. Martindale ‑ The Extra Pharmacopeia. London:
The Pharmaceutical Press; 1991.
Pajus I, Lestang P, Liote F, Dryll A. Erythroderma after
clodronate treatment. Br Med J 1993;307:484.
Bonefos® 400mg capsules. Available from: http://www.
mhra.gov.uk/home/groups/spcpil/documents/spcpil/
con1474003403151.pdf. [Last accessed on 2018 Sep 08].
Lalinga AV, Pellegrino M, Laurini L, Miracco C. Necrobiotic
palisading granuloma at injection site of disodium clodronate:
A case report. Dermatology 1999;198:394‑5.
Product Information: Didronel(R) Oral Tablets, Etidronate
Disodium Oral Tablets. Rockaway, NJ: Warner Chilcott (US),
LLC (per Manufacturer); 2011.
Product Information: BONIVA(R) Oral Tablets, ibandronate
Sodium Oral Tablets. South San Francisco, CA: Genentech USA,
Inc. (per Manufacturer); 2015.
Risedronate sodium 35 mg film‑coated tablets. Available from:
https://mri.cts‑mrp.eu/Human/Downloads/DK_H_2019_001_
FinalPI_7of8.pdf. [Last accessed on 2018 Sep 08].
Kashyap AS, Kashyap S. Hypoparathyroidism unmasked by
alendronate. Postgrad Med 2000;76:417‑9.
Product Information: BINOSTO(R) Oral Effervescent Tablets,
Alendronate Sodium Oral Effervescent Tablets. San Antonio,
TX: Mission Pharmacal Company (per FDA); 2013.
Whitson HE, Lobaugh B, Lyles KW. Severe hypocalcemia
following bisphosphonate treatment in a patient with Paget’s
disease of bone. Bone 2006;39:954‑8.
Jones SG, Dolan G, Lengyel K, Myers B. Severe increase in
creatinine with hypocalcaemia in thalidomide‑treated myeloma
patients receiving zoledronic acid infusions. Br J Haematol
;119:576‑7.
Jacobs TP, Siris ES, Bilezikian JP, Baquiran DC, Shane E,
Canfield RE. Hypercalcemia of malignancy: Treatment with
intravenous dichloromethylene diphosphonate. Ann Intern Med
;94:312‑6.
Shane E, Jacobs TP, Siris ES, Steinberg SF, Stoddart K,
Canfield RE, et al. Therapy of hypercalcemia due to parathyroid
carcinoma with intravenous dichloromethylene diphosphonate.
Am J Med 1982;72:939‑44.
Altman RD, Johnston CC, Khairi MR, Wellman H, Serafini AN,
Sankey RR. Influence of disodium etidronate on clinical and
laboratory manifestations of Paget’s disease of bone (osteitis
deformans). N Engl J Med 1973;289:1379‑84.
BONIVA(R) Intravenous Injection, Ibandronate Intravenous
Injection. South San Francisco, CA: Genentech USA, Inc.
(per FDA); 2013.
Vitale G, Fonderico F, Martignetti A, Caraglia M, Ciccarelli A,
Nuzzo V, et al. Pamidronate improves the quality of life and
induces clinical remission of bone metastases in patients with
thyroid cancer. Br J Cancer 2001;84:1586‑90.
Product Information: ATELVIA(TM) Delayed‑Release Oral
Tablets, Risedronate Sodium Delayed‑Release Oral Tablets.
Rockaway, NJ: Warner Chilcott (US), LLC; 2010. p. 43
Alendronate (Oral route). Available from: https://www.
mayoclinic.org/drugs‑supplements/alendronate‑oral‑route/
side‑effects/drg‑20061571. [Last accessed on 2018 Sep 08].
U.S. Food and Drug Administration (FDA): FDA Drug Safety
Communication: Ongoing Safety Review Of Oral Osteoporosis
Drugs (Bisphosphonates) and Potential Increased Risk of
Esophageal Cancer. Rockville, MD: U.S. Food and Drug
Administration (FDA); 2011.
Oh YH, Yoon C, Park SM. Bisphosphonate use and
gastrointestinal tract cancer risk: Meta‑analysis of observational
studies. World J Gastroenterol 2012;18:5779‑88.
Abrahamsen B, Eiken P, Eastell R. More on reports of
esophageal cancer with oral bisphosphonate use. N Engl J Med
;360:1789, 1791‑2.
Khapra AP, Rose S. Drug injury in the upper gastrointestinal
tract: Effects of alendronate. Gastrointest Endosc Clin N Am
;16:99‑110.
Kennel KA, Drake MT. Adverse effects of bisphosphonates:
Implications for osteoporosis management. Mayo Cli Prac
;84:632‑8.
Nussbaum SR, Warrell RP Jr, Rude R, Glusman J, Bilezikian JP,
Stewart AF, et al. Dose‑response study of alendronate sodium
for the treatment of cancer‑associated hypercalcemia. J Clin
Oncol 1993;11:1618‑23.
Halabe A, Lifschitz BM, Azuri J. Liver damage due to
alendronate. N Engl J Med 2000;343:365‑6.
Goossens N, Spahr L, Rubbia‑Brandt L. Severe
immune‑mediated drug‑induced liver injury linked to
ibandronate: A case report. J Hepatol 2013;59:1139‑42.
Center for drug evaluation and research. Ibandronate Sodium.
Available from: https://www.accessdata.fda.gov/drugsatfda_docs/
nda/2008/021455Orig1s007.pdf. [Last assessed on 2019 Aug 28].
Risedronate side effects. Available from: https://www.drugs.com/
sfx/risedronate‑side‑effects.html#refs. [Last assessed on 2019
Aug 28].
Hortobbagyi Gn, Theriault RL, Lipton A, Porter L,
Blayney D, Sinoff C, et al. Long‑term prevention of skeletal
complications of metastatic breast cancer with pamidronate.
Protocol 19 Aredria Breast Cancer Study group. J Clin Oncol
;16:2038‑44.
Wysowski DK, Chang JT. Alendronate and risedronate: Reports
of severe bone, joint, and muscle pain. Arch Intern Med
;165:346‑7.
US Food and Drug Administration: Information for Healthcare
Professionals Bisphosphonates (marketed as Actonel,
Actonel+Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax+D,
Reclast, Skelid, and Zometa). Available from: https://www.
albany.edu/sph/cphce/sta/attachment_16.pdf. [Last assessed on
Aug 28].
Lenart BA, Lorich DG, Lane JM. Atypical fractures of femoral
diaphysis in postmenopausal women taking alendronate. N Eng
J Med 2008;358:1304‑6.
Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA,
Pak CY. Severely suppressed bone turnover: A potential
complication of alendronate therapy. J Clin Endocrinol Metab
;90:1294‑301.
Park‑Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA,
Gunraj N, Austin PC, et al. Bisphosphonate use and the risk
of subtrochanteric or femoral shaft fractures in older women.
JAMA 2011;305:783‑9.
U.S. Food and Drug Administration: FDA Safety
Communication: Safety Update for Osteoporosis Drugs,
Bisphosphonates and Atypical Fractures. Rockville, MD: U.S.
Food and Drug Administration; 2010.
Orozco C, Maalouf NM. Safety of bisphosphonates. Rheum Dis
Clin North Am 2012;38:681‑705.
Marx RE. Pamidronate (Aredia) and zoledronate (Zometa)
induced avascular necrosis of the jaws: A growing epidemic.
J Oral Maxillofac Surg 2003;61:1115‑7.
Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review:
Bisphosphonates and osteonecrosis of the jaws [published
correction appears in Ann Intern Med 2006;145:235]. Ann Intern
Med 2006;144:753‑61.
Dimopoulos MA, Kastritis E, Anagnostopoulos A,
Melakopoulos I, Gika D, Moulopoulos LA, et al. Osteonecrosis
of the jaw in patients with multiple myeloma treated with
bisphosphonates: Evidence of increased risk after treatment with
zoledronic acid. Haematologica 2006;91:968‑71.
Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL.
Osteonecrosis of the jaws associated with the use of
bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg
;62:527‑34.
Coskun Benlidayi I, Guzel R. Oral bisphosphonate related
osteonecrosis of the jaw: A challenging adverse effect. ISRN
Rheumatol 2013;2013:215034. doi: 10.1155/2013/215034.
Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR,
Felsenberg D, et al. Bisphosphonate‑associated osteonecrosis
of the jaw: Report of a task force of the American Society
for Bone and Mineral Research [editorial]. J Bone Miner Res
;22:1479‑91.
Hershman DL, McMahon DJ, Crew KD, Cremers S, Irani D,
Cucchiara G, et al. Zoledronic acid prevents bone loss in
premenopausal women undergoing adjuvant chemotherapy for
early‑stage breast cancer. J Clin Oncol 2008;26:4739‑45.
Smith MR, Eastham J, Gleason DM, Shasha D,
Tchekmedyian S, Zinner N. Randomized controlled trial of
zoledronic acid to prevent bone loss in men receiving androgen
deprivation therapy for nonmetastatic prostate cancer. J Urol
;169:2008‑12.
Abu‑Id MH, Warnke PH, Gottschalk J, Springer I, Wiltfang J,
Acil Y, et al. Bis‑phossy jaws‑ High and low risk factors
for bisphosphonate‑induced osteonecrosis of the jaw.
J Craniomaxillofac Surg 2008;36:95‑103.
Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K,
de Boer RH, et al. Denosumab compared with zoledronic acid
for the treatment of bone metastases in patients with advanced
breast cancer: A randomized, double‑blind study. J Clin Oncol
;28:5132‑9.
Sim IW, Sanders KM, Borromeo GL, Seymour JF, Ebeling PR.
Declining incidence of medication‑related osteonecrosis of
the jaw in patients with cancer. J Clin Endocrinol Metab
;100:3887‑93.
Baron R, Ferrari S, Russell RG. Denosumab and
bisphosphonates: Different mechanisms of action and effects.
Bone 2011;48:677‑92.
Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, et al. Zoledronic acid induces significant and
long‑lasting modifications of circulating angiogenic factors in
cancer patients. Clin Cancer Res 2003;9:2893‑7.
Stepan JJ, Burr DB, Pavo I, Sipos A, Michalska D, Li J, et al.
Low bone mineral density is associated with bone microdamage
accumulation in postmenopausal women with osteoporosis.
Bone 2007;41:378‑85.
Ruggiero SL. Bisphosphonate‑related Osteonecrosis of the Jaws.
Compend Contin Educ Dent 2008;29:97‑105.
Product Information: BINOSTO(TM) Oral Effervescent Tablets,
Alendronate Sodium Oral Effervescent Tablets. San Antonio,
TX: Mission Pharmacal Company (per FDA); 2012.